A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer
Metrics: PDF 2666 views | HTML 2311 views | ?
Zhongping Cheng1,2, Jing Guo1,2, Li Chen1,2, Ning Luo1,2, Weihong Yang1,2, Xiaoyan Qu1,2
1Department of Obstetrics and Gynecology, Yangpu Hospital, Tongji University School of Medicine, Shanghai, PR China
2Institute of Gynecological Minimally Invasive Medicine, Tongji University School of Medicine, Shanghai, PR China
ZhongPing Cheng, e-mail: [email protected]
Keywords: lincRNA, AB073614, ovarian cancer, RNAi
Received: March 20, 2015 Accepted: July 17, 2015 Published: July 30, 2015
Long noncoding RNA (lncRNA) profiles in ovarian cancer (OC) remain largely unknown. In the present study, we screened AB073614 as a new candidate lncRNA which promotes development of OC, in two independent datasets (GSE18521 and GSE38666) from the Gene Expression Omnibus (GEO). The level of AB073614 was then detected in 75 paired OC tissues and adjacent normal tissues by qRT-PCR. Results showed that AB073614 expression was significantly up-regulated in 85.3% (64/75) cancerous tissues compared with normal counterparts (P < 0.01). Further, the 5-year overall survival (OS) in OC patients with high expression of AB073614 was inferior to that with low expression (17.2 months vs 30.0 months, P = 0.0025). To investigate the functional role of AB073614, AB073614 siRNA was transfected into OC cell lines. Knockdown of AB073614 expression significantly inhibited cell proliferation and invasion, resulted in cell arrest in G1 phase of cell cycle and a dramatic increase of apoptosis, both in HO-8910 and OVCAR3 cells. In vivo experiment also revealed that knockdown AB073614 inhibited OVCAR3 cells proliferation. Finally, western blot assays indicated that lncRNA AB073614 may exert its function by targeting ERK1/2 and AKT-mediated signaling pathway. In conclusion, our study suggests that lncRNA AB073614 acts as a functional oncogene in OC development.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.